All In Biotech

Drug Trial Radar · NCT01663402

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

Last checked: Nov 19, 2026Latest source record: Mar 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 18,924 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

18,924

Actual

Start

Oct 2012

Primary completion

Jan 23, 2018

Study completion Jan 23, 2018

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Aug 13, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To compare the effect of alirocumab with placebo on the occurrence of cardiovascular (CV) events (composite endpoint of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), fatal and non-fatal ischemic stroke, unstable angina (UA) requiring hospitalization) in participants who experienced an acute coronary syndrome (ACS) event 4 to 52 weeks prior to randomization and were treated with evidence-based medical and dietary management of dyslipidemia. Secondary Objectives: * To evaluate the effect of alirocumab on secondary endpoints (any CHD event , major CHD event, any CV event, composite of all cause mortality/non-fatal MI/non-fatal ischemic stroke, CHD deaths, CV deaths, all cause mortality). * To evaluate the safety and tolerability of alirocumab. * To evaluate the effect of alirocumab on lipid parameters.

Conditions

  • Atherosclerotic Cardiovascular Disease

Interventions

  • AlirocumabDrug

    Alirocumab administered as SC injection of 1 mL in the abdomen or thigh with a disposable auto-injector.

  • PlaceboDrug

    Placebo matched to alirocumab administered as a SC injection of 1 mL in the abdomen or thigh with a disposable auto-injector.

  • LMTDrug

    Statins (atorvastatin or rosuvastatin) at stable maximal tolerated dose of statin with or without other LMT as clinically indicated.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Occurrence of Major Adverse Cardiovascular Event (MACE); Percentage of Observed Participants With Outcome Measure Events During the StudyTime frame: From randomization up to 64 months

Locations

1,388 sites in 57 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 840163

    Birmingham, Alabama

  • Investigational Site Number 840060

    Birmingham, Alabama

  • Investigational Site Number 840117

    Huntsville, Alabama

  • Investigational Site Number 840192

    Huntsville, Alabama

  • Investigational Site Number 840121

    Mobile, Alabama

  • Investigational Site Number 840319

    Mobile, Alabama

  • Investigational Site Number 840332

    Atlantis, Arizona

  • Investigational Site Number 840320

    Newport Beach, Arizona

  • Investigational Site Number 840103

    Tucson, Arizona

  • Investigational Site Number 840084

    Tucson, Arizona

  • Investigational Site Number 840139

    Banning, California

  • Investigational Site Number 840286

    Beverly Hills, California

  • Investigational Site Number 840246

    Beverly Hills, California

  • Investigational Site Number 840353

    Beverly Hills, California

  • Investigational Site Number 840341

    Carmichael, California

  • Investigational Site Number 840299

    Chula Vista, California

  • Investigational Site Number 840164

    Fresno, California

  • Investigational Site Number 840076

    Fullerton, California

  • Investigational Site Number 840073

    Huntington Beach, California

  • Investigational Site Number 840092

    La Jolla, California

  • Investigational Site Number 840208

    Long Beach, California

  • Investigational Site Number 840068

    Long Beach, California

  • Investigational Site Number 840269

    Los Alamitos, California

  • Investigational Site Number 840009

    Los Angeles, California

  • Investigational Site Number 840282

    Los Angeles, California

  • Investigational Site Number 840019

    Mission Viejo, California

  • Investigational Site Number 840336

    Moreno Valley, California

  • Investigational Site Number 840124

    Northridge, California

  • Investigational Site Number 840251

    Pasadena, California

  • Investigational Site Number 840289

    Pasadena, California

  • Investigational Site Number 840312

    Port Hueneme, California

  • Investigational Site Number 840261

    San Diego, California

  • Investigational Site Number 840310

    San Diego, California

  • Investigational Site Number 840024

    San Diego, California

  • Investigational Site Number 840071

    Santa Ana, California

  • Investigational Site Number 840236

    Santa Rosa, California

  • Investigational Site Number 840012

    Torrance, California

  • Investigational Site Number 840096

    Aurora, Colorado

  • Investigational Site Number 840037

    Colorado Springs, Colorado

  • Investigational Site Number 840189

    Denver, Colorado

Showing 40 of 1,388 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.